{"id":"tislelizumab-carboplatin-paxlitaxel","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Rash"},{"rate":"10-20%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL4297840","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tislelizumab is a PD-1 inhibitor, which means it works by blocking the PD-1/PD-L1 axis. This blockade allows the immune system to recognize and attack cancer cells more effectively. Tislelizumab has been shown to be effective in treating various types of cancer, including non-small cell lung cancer, esophageal squamous cell carcinoma, and hepatocellular carcinoma.","oneSentence":"Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response. By binding to PD-1, tislelizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and other cells in the tumor microenvironment. This blockade enhances the immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:54.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Esophageal squamous cell carcinoma"},{"name":"Hepatocellular carcinoma"}]},"trialDetails":[{"nctId":"NCT05840016","phase":"PHASE3","title":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-08-17","conditions":"Advanced Squamous Non Small Cell Lung Cancer","enrollment":532}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tislelizumab, Carboplatin, Paxlitaxel","genericName":"Tislelizumab, Carboplatin, Paxlitaxel","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response. By binding to PD-1, tislelizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and other cells in the tumor microenvironment. This blockade enhances the immune response against cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Esophageal squamous cell carcinoma, Hepatocellular carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}